Kamada launches two biosimilars in Israel, doubling marketed portfolio to four

Kamada (NASDAQ: KMDA) launched Ustekinumab-Kamada (Stelara biosimilar) and Enoxaparin-Kamada (Clexane biosimilar) in Israel, doubling its marketed biosimilar portfolio from two to four products, all approved and launched as interchangeable. The company also issued 2030 revenue guidance.

Detected & updated continuously · Source: Nebula